Davunetide vs Semax
How Davunetide and Semax compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Davunetide and Semax come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Davunetide vs Semax, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Davunetide | Semax |
|---|---|---|
| What it is | Synthetic neuroprotective octapeptide derived from activity-dependent neuroprotective protein (ADNP) | Synthetic heptapeptide — an analog of ACTH(4-10) (the Met-Glu-His-Phe fragment with a Pro-Gly-Pro tail added for stability) |
| Class / category | Nootropic / mental-health | Nootropic / mental-health |
| Evidence tier | Human RCT · No effect | Animal-only · Unclear |
| Studied / approved for | Progressive supranuclear palsy (PSP); Amnestic mild cognitive impairment; Cognitive impairment in schizophrenia; ADNP syndrome | Cognitive enhancement / focus; Neuroprotection after ischemic stroke; Attention and mood support |
| US regulatory status (2026) | investigational (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 0 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | No |
| Key risks | Davunetide was generally well tolerated in the 52-week PSP trial, but intranasal treatment caused more nasal congestion, discomfort, runny nose, and nosebleeds. Serious adverse events were equally numerous in the treatment and placebo groups. That trial does not establish long-term safety in healthy people using an unapproved product for cognitive enhancement. | Semax is generally reported as well tolerated, and Russia's decades of clinical use as a nasal medicine is reassuring. But rigorous long-term Western safety data is limited, most controlled data comes from short courses, and the research-grade powder sold outside Russia is unregulated — so what a given vial actually contains — purity, true dose, sterility — comes down to the seller. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Davunetide vs Semax: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward Davunetide
Davunetide's evidence sits at human rct, a more human tier than Semax's animal-only. That reflects how the data was gathered, not a guarantee it works.
References
- 1.Boxer et al., 2014 — davunetide in progressive supranuclear palsy (PMID 24873720; PMCID PMC4129545)
- 2.Morimoto et al., 2013 — AL-108 in amnestic mild cognitive impairment (PMID 23594991)
- 3.Javitt et al., 2012 — davunetide in schizophrenia (PMID 22169248)
- 4.PubChem — Davunetide, CID 9832404
- 5.FDA orphan designation record — davunetide for ADNP syndrome
- 6.Shapira et al., 2026 — sex-stratified reanalysis of the PSP davunetide trial